Antibodies for
Alzheimer’s disease.

Peptide targets are often challenging because they typically exhibit low immunogenicity and limited structural complexity compared to full-length proteins. As a result, antibodies generated using standard approaches may show poor affinity, low specificity or fail during downstream validation. At BioClonal, we develop custom immunization strategies specifically optimized for peptide targets, helping biotech and pharmaceutical companies generate reliable peptide antibodies for complex applications.

How do you generate antibodies against low-immunogenic peptides?

At BioClonal, we use immunogen design approaches engineered to improve immune recognition against low-immunogenic peptide targets. Each project is developed using a bespoke strategy adapted to the peptide sequence, target biology and final application requirements. Our workflow combines peptide-focused immunization, optimized screening and advanced validation to maximize the probability of obtaining high-performance antibodies.

What are peptide antibodies used for?

Peptide antibodies are widely used in research, diagnostics and therapeutic discovery. They are particularly valuable for detecting specific protein regions, post-translational modifications, conformational epitopes and disease-related biomarkers. Applications commonly include ELISA, Western Blot, Immunohistochemistry (IHC), Immunofluorescence (IF), biomarker discovery and diagnostic assay development.

Project timelines depend on the target complexity, immunization strategy and downstream validation requirements. In most cases, early screening data can be generated within a few months, while fully validated monoclonal antibody programs typically require additional development time. At BioClonal, every project is designed using a customized workflow focused on maximizing antibody performance and application-specific validation.

Can you work from a peptide sequence only?

Yes. BioClonal can initiate antibody development projects starting from a peptide sequence alone. Our team analyzes the peptide target, epitope characteristics and intended downstream application to design a proprietary Superimmunogen specifically optimized for the project. This customized immunogen design strategy enhances immune recognition against challenging peptide targets and supports the generation of high-performance peptide antibodies for research, diagnostic and therapeutic applications.

Yes. BioClonal develops antibodies against peptide targets associated with neurodegenerative diseases, including Alzheimer’s disease. Our expertise includes challenging peptide epitopes, aggregated proteins and disease-related conformational targets. In addition to custom antibody services, BioClonal is advancing internal research programs focused on next-generation antibodies against pathological Aβ-related species.